Clinical Trial Update: Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the immunogenicity, safety, and efficacy of Zarzio/Filgrastim HEXAL in patients with Severe Chronic Neutropenia; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• Zarzio/Filgrastim HEXAL (filgrastim)

Snippet

Sponsor: Sandoz | Conditions: Severe Chronic Neutropenia | Phase 4 | Status: TERMINATED | Results posted: 2016-03-28